3 Professional Societies Issue Joint Guidelines for Prostate Cancer Care

3 Professional Societies Issue Joint Guidelines for Prostate Cancer Care

Three professional societies — the American Urological Association, the American Society for Radiation Oncology and the Society of Urologic Oncology — have issued a series of evidence-based clinical guidelines on how to manage localized prostate cancer.

The recommendations urge physicians to take cancer severity into account when considering treatment option, but also stress the importance of shared treatment decision-making, in which physician explain and guide their patients through the many options available.

“Selecting optimal care for each prostate cancer patient is a complex process that requires physicians to help patients choose options consistent with the patient’s own values and in accordance with the best available scientific evidence,” Dr. Martin G. Sanda, MD, chair of the guideline development panel and the urology department at Atlanta’s Emory School of Medicine, said in a press release.

“The new clinical guideline offers a framework to facilitate such shared decision-making, while also specifying which cancers are better managed by active surveillance, as well as providing guidance as to which treatments are appropriate for cancers warranting intervention,” said Sanda. “It also provides specifics for implementing care options, managing side effects and administering post-treatment follow-up.”

Before it was finalized, many peer reviewers with various backgrounds approved the document, which offers suggestions on how to best manage localized prostate cancer of varying risk groups.

Localized prostate cancer — the type that hasn’t spread outside the prostate — that is deemed to have a low risk of spreading or becoming aggressive, is best managed with active surveillance, suggest the guidelines, which recommend radical prostatectomy or radiotherapy in combination with androgen-deprivation therapy for men with intermediate or high-risk tumors.

Since risk stratification is at the core of the guidelines, there’s an entire section defining low, intermediate and high-risk tumors. The document, which contains 68 statements, also offers advice on managing side effects and what to expect from various treatment outcomes, including health-related quality of life.

U.S. doctors will likely diagnose more than 161,000 cases of prostate cancer in 2017. An estimated one in seven men will develop this disease during their lives. However, their odds increase to one in five if they are African-American, and one in three if prostate cancer runs in their families.

 

One comment

  1. Lawrence Glickman says:

    I could not disagree more with the “watchful waiting” point of view being promoted by insurance companies and urologists and government agencies who are not on the cutting edge of new treatments and in many cases are using outdated associative studies and ancient diagnostic techniques. 1. There is no value to age weighted PSA interpretations. An organ is either healthy or its not. Telling a man in his 70’s that his PSA of 2.5 to 4 is OK is insulting as he may live to 100! Further testing is called for http://drcatalona.com/quest/Winter04/quest_winter04_6.asp
    2. Most old fashioned 10 needle biopsies often miss significant cancer. MRI or at least Color doppler guided biopsies give a better result with confirmative PCA3 and other chemical tests. 3. Why would prostate cancer by the one cancer where early treatment is not an advantage? This is absurd especially with the new focal (local) treatment options like cyro,hifu,laser, Toocad and the stellar results just announced by Cyber Knife for early stage cases. 4. Associative studies about mortality etc have one major flaw,show me one oncologist that can promise that while the patient is “waiting” that he will guarantee that no metastasis will happen and the patient will not face intractable bone or organ cancer. You will not find one. 5. My father died of late treatment and brother at 83 is prostate cancer free for 15 years due to early treatment. Who would you rather be?

Leave a Comment

Your email address will not be published. Required fields are marked *